Vidac Pharma is a clinical-stage pharmaceutical company focused on discovering and developing first-in-class small-molecule therapies for oncologic and oncodermatologic diseases. Its lead product, VDA-1102, is a topical ointment that completed Phase 1 and is currently in a Phase 2 clinical trial for actinic keratosis. The company’s technology targets the cancer-specific VDAC/HK2 system to induce selective apoptosis of malignant cells while sparing healthy tissue. Vidac plans to use the new financing to advance VDA-1102 through clinical development and to progress its broader pipeline into clinical studies. The company emphasizes translating breakthroughs in mitochondria and cancer metabolism into therapies that are both efficacious and well tolerated. Financially, Vidac has just closed a financing to support these clinical and development plans.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2016